JP2024150637A5 - - Google Patents
Info
- Publication number
- JP2024150637A5 JP2024150637A5 JP2024117419A JP2024117419A JP2024150637A5 JP 2024150637 A5 JP2024150637 A5 JP 2024150637A5 JP 2024117419 A JP2024117419 A JP 2024117419A JP 2024117419 A JP2024117419 A JP 2024117419A JP 2024150637 A5 JP2024150637 A5 JP 2024150637A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- treatment
- hmwk
- truncated hmwk
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893505P | 2013-10-21 | 2013-10-21 | |
| US61/893,505 | 2013-10-21 | ||
| US201461939837P | 2014-02-14 | 2014-02-14 | |
| US61/939,837 | 2014-02-14 | ||
| JP2020144118A JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137393A Division JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024150637A JP2024150637A (ja) | 2024-10-23 |
| JP2024150637A5 true JP2024150637A5 (https=) | 2025-10-10 |
Family
ID=52993413
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549206A Active JP6757252B2 (ja) | 2013-10-21 | 2014-10-17 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A Active JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2024117419A Pending JP2024150637A (ja) | 2013-10-21 | 2024-07-23 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549206A Active JP6757252B2 (ja) | 2013-10-21 | 2014-10-17 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| JP2022137393A Active JP7668772B2 (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11372002B2 (https=) |
| EP (2) | EP3060582B1 (https=) |
| JP (4) | JP6757252B2 (https=) |
| KR (4) | KR20230054745A (https=) |
| CN (1) | CN105873951A (https=) |
| AU (3) | AU2014340450B2 (https=) |
| BR (1) | BR112016008970B1 (https=) |
| CA (1) | CA2927824C (https=) |
| DK (1) | DK3060582T3 (https=) |
| ES (1) | ES2837858T3 (https=) |
| IL (3) | IL289514B2 (https=) |
| PL (1) | PL3060582T3 (https=) |
| WO (1) | WO2015061183A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| KR102320178B1 (ko) * | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| EP4234583A3 (en) * | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| KR102607829B1 (ko) * | 2015-03-30 | 2023-12-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 |
| JP6907188B2 (ja) | 2015-08-13 | 2021-07-21 | ダイアックス コーポレーション | 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管 |
| EP4354146B1 (en) | 2015-10-19 | 2026-04-15 | Takeda Pharmaceutical Company Limited | Immunoassay for the detection of cleaved high molecular weight kininogen |
| KR102874711B1 (ko) * | 2015-12-15 | 2025-10-23 | 다케다 파머수티컬 컴패니 리미티드 | 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 |
| US11340237B2 (en) * | 2016-09-16 | 2022-05-24 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| IL265195B2 (en) * | 2016-09-16 | 2025-02-01 | Dyax Corp | Protein biomarkers for diseases related to the activation system |
| EA201990730A1 (ru) | 2016-09-16 | 2019-08-30 | Дайэкс Корп. | Рнк-биомаркеры для наследственного ангионевротического отека |
| EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
| WO2019165308A1 (en) * | 2018-02-22 | 2019-08-29 | The Regents Of The University Of California | Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema |
| CN111057745B (zh) * | 2019-12-30 | 2022-08-12 | 中国科学院生态环境研究中心 | 一种物质的血液毒性效应的高通量筛选方法 |
| EP4090427A1 (en) | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| US20230174674A1 (en) * | 2020-04-04 | 2023-06-08 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| CN113777331A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液激肽原-1及其多肽片段在烧伤中的应用 |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
| EP4548103A2 (en) * | 2022-06-30 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
| WO2025153806A1 (en) * | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPS63185398A (ja) * | 1986-09-10 | 1988-07-30 | Nippon Zoki Pharmaceut Co Ltd | 生理活性物質測定法 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1993003748A1 (en) | 1991-08-13 | 1993-03-04 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| WO1995021601A2 (en) | 1994-01-11 | 1995-08-17 | Protein Engineering Corporation | Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof |
| JPH1084995A (ja) | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| ES2348230T3 (es) | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| WO2004005934A2 (en) | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) * | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| PL1981519T3 (pl) | 2005-12-29 | 2018-07-31 | Dyax Corp. | Hamowanie proteaz |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| JP2010510528A (ja) | 2006-11-22 | 2010-04-02 | ライフ テクノロジーズ コーポレーション | 自己免疫疾患のバイオマーカー |
| US20090075887A1 (en) | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| US8263347B2 (en) | 2007-10-18 | 2012-09-11 | Miyazaki Prefectural Industrial Support Foundation | Biomarker for diagnosis of liver disease |
| AU2008315938B2 (en) * | 2007-10-22 | 2014-11-27 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| CA2729937A1 (en) | 2008-07-07 | 2010-01-14 | Nippon Zoki Pharmaceutical Co., Ltd. | Fibromyalgia test method |
| JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2369930A4 (en) | 2008-12-02 | 2012-10-03 | Joslin Diabetes Ct | METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| FR2942233B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| KR101077275B1 (ko) | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| AU2010330743A1 (en) | 2009-12-18 | 2012-07-05 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| WO2012009447A2 (en) | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| EP2645932B1 (en) | 2010-12-02 | 2016-03-02 | Becton, Dickinson and Company | Blood collection devices containing blood stabilization agent |
| KR102320178B1 (ko) * | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| EP3320922A1 (en) * | 2011-06-10 | 2018-05-16 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
| WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| FR2983215B1 (fr) * | 2011-11-28 | 2013-12-20 | Univ Grenoble 1 | Dosage de la capacite de controle de c1inh |
| EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| RU2015136025A (ru) | 2013-02-01 | 2017-03-06 | Бектон, Дикинсон энд Кампани | Устройства для сбора крови, содержащие добавки, ингибирующие контактный путь свертывания крови |
| WO2015061183A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| EP4354146B1 (en) | 2015-10-19 | 2026-04-15 | Takeda Pharmaceutical Company Limited | Immunoassay for the detection of cleaved high molecular weight kininogen |
| KR102874711B1 (ko) | 2015-12-15 | 2025-10-23 | 다케다 파머수티컬 컴패니 리미티드 | 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법 |
| EP4096687A4 (en) | 2020-01-28 | 2024-02-28 | Orgenesis Inc. | Process and system for acellular therapy |
-
2014
- 2014-10-17 WO PCT/US2014/061247 patent/WO2015061183A1/en not_active Ceased
- 2014-10-17 ES ES14856778T patent/ES2837858T3/es active Active
- 2014-10-17 CN CN201480070281.6A patent/CN105873951A/zh active Pending
- 2014-10-17 KR KR1020237012295A patent/KR20230054745A/ko not_active Ceased
- 2014-10-17 BR BR112016008970-7A patent/BR112016008970B1/pt active IP Right Grant
- 2014-10-17 KR KR1020227027698A patent/KR102521947B1/ko active Active
- 2014-10-17 EP EP14856778.7A patent/EP3060582B1/en active Active
- 2014-10-17 IL IL289514A patent/IL289514B2/en unknown
- 2014-10-17 CA CA2927824A patent/CA2927824C/en active Active
- 2014-10-17 PL PL14856778T patent/PL3060582T3/pl unknown
- 2014-10-17 EP EP20197583.6A patent/EP3808857B1/en active Active
- 2014-10-17 JP JP2016549206A patent/JP6757252B2/ja active Active
- 2014-10-17 KR KR1020257014548A patent/KR20250066486A/ko active Pending
- 2014-10-17 DK DK14856778.7T patent/DK3060582T3/da active
- 2014-10-17 US US15/030,811 patent/US11372002B2/en active Active
- 2014-10-17 KR KR1020167013432A patent/KR102432826B1/ko active Active
- 2014-10-17 AU AU2014340450A patent/AU2014340450B2/en active Active
-
2016
- 2016-04-19 IL IL245205A patent/IL245205B/en active IP Right Grant
-
2020
- 2020-04-19 IL IL274055A patent/IL274055B/en unknown
- 2020-08-10 AU AU2020217316A patent/AU2020217316B2/en active Active
- 2020-08-28 JP JP2020144118A patent/JP7135039B2/ja active Active
-
2021
- 2021-12-20 US US17/555,636 patent/US12442824B2/en active Active
-
2022
- 2022-08-31 JP JP2022137393A patent/JP7668772B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203355A patent/AU2024203355A1/en active Pending
- 2024-07-23 JP JP2024117419A patent/JP2024150637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024150637A5 (https=) | ||
| Mast et al. | SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung | |
| Winterbourn et al. | Elevated protein carbonyls as plasma markers of oxidative stress in acute pancreatitis | |
| JP2016536012A5 (https=) | ||
| JP2022141640A5 (https=) | ||
| JP2024026847A5 (https=) | ||
| Alexander et al. | Association between γ′ fibrinogen levels and inflammation | |
| Ota et al. | High plasma level of factor VIII–an important risk factor for venous thromboembolism– | |
| JP2021523744A (ja) | 脳卒中の血液バイオマーカー | |
| CN103582818A (zh) | 戈谢病的诊断方法 | |
| Hoshino et al. | Validating plasminogen activator inhibitor‐1 as a poor prognostic factor in sepsis | |
| US20190323060A1 (en) | Fibrosis susceptibility il22ra2 gene and uses thereof | |
| Carlton et al. | Biomarkers in pediatric acute respiratory distress syndrome | |
| JP4463460B2 (ja) | Ｘａ因子阻害剤の活性をモニターするためラッセルクサリヘビ蛇毒誘導血漿Ｘａ因子活性の使用 | |
| JP5118321B2 (ja) | ヘパリン修飾成分を用いた第Ｘａ因子に基づくヘパリンアッセイ | |
| Iribarren et al. | Postoperative bleeding in cardiac surgery: the role of tranexamic acid in patients homozygous for the 5G polymorphism of the plasminogen activator inhibitor-1 gene | |
| Sonnevi et al. | Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18–65 years | |
| RU2657760C1 (ru) | Способ раннего прогнозирования риска возникновения тромбоэмболических осложнений у пациентов с ишемической болезнью сердца после реваскуляризации миокарда методом аортокоронарного шунтирования | |
| Parikh et al. | Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure | |
| Nishiuma et al. | Localization of plasminogen activator activity within normal and injured lungs by in situ zymography | |
| Popa et al. | Non-invasive Serological Markers of Hepatic Fibrosis–Mini Review | |
| Arapoglou et al. | The influence of total plasma homocysteine and traditional atherosclerotic risk factors on degree of abdominal aortic aneurysm tissue inflammation | |
| US7264936B2 (en) | Method for detecting procoagulant genetic and metabolic conditions associated with, and potentially predispositional for, activation of the coagulation response | |
| Novida et al. | Mortality prediction model in patients with diabetic foot ulcer: A case-control study from a tertiary referral hospital in Surabaya, Indonesia | |
| RU2835822C9 (ru) | Способ определения антикоагулянтного потенциала плазмы крови для диагностики предтромботических состояний |